Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.30 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25624436 | 0.87 | GRM4 (0.33) | — | |
| SCHEMBL25613040 | 0.86 | MAPK1 (0.31) | MAPK1MAP3K7TAB1 | |
| SCHEMBL25624362 | 0.83 | CDK1 (0.34) | CDK1 | |
| SCHEMBL25627364 | 0.81 | MAP3K7 (0.33) | MAP3K7TAB1 | |
| SCHEMBL25650927 | 0.81 | CDK1 (0.33) | CDK1 | |
| SCHEMBL25624434 | 0.80 | MERTK (0.35) | MAPK1 | |
| SCHEMBL25626737 | 0.79 | LRRK2 (0.34) | — | |
| SCHEMBL25613047 | 0.76 | KDR (0.39) | MAPK1CDK1 | |
| SCHEMBL25613042 | 0.76 | MAP3K7 (0.37) | MAP3K7TAB1CDK1 | |
| SCHEMBL25624105 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | MAPK1 2612/4885MAP3K7 2282/4885TAB1 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.